Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Илопрост – доступный простациклин для терапии легочной артериальной гипертензии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Морман Д., Хеллер Л. Физиология сердечно-сосудистой системы. СПб.: Питер, 2000.
2. Fetalvero KM, Martin KA, Hwa J. Cardioprotective prostacyclin signaling in vascular smooth musle. Prostaglandins Other Lipid Mediators 2007; 82: 109–18.
3. Мари Р., Гренер Д., Мейес П. Метаболизм ненасыщенных жирных кислот и эйказаноидов. М.: Мир, 1993.
4. Ольбинская Л.И., Литвицкий П.Ф. Коронарная и миокардиальная недостаточность. М.: Медицина, 1986.
5. Moncada S, Vane J. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmac Rev 1979; 30: 292–305.
6. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Современные подходы к лечению пациентов с легочной гипертензией в свете рекомендаций Европейского Общества кардиологов. Cons. med. 2005;7 (11): 957–62.
7. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–9.
8. Olschewski H, Hoeper MM, Behr J et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 2010; 104: 731–40.
9. Guo XX, Tian Z, Liu YT et al. Effects of inhaled aerosolized iloprost in adult patients with pulmonary arterial hypertension on right heart functions. Zhonghua Yi Xue Za Zhi 2011; 40 (91): 2832–6.
10. Gabrielli LA, Castro PF, Godoy I et al. Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients. J Card Fail 2011; 12 (17): 1012–7.
11. Birukova AA, Wu T, Tian Y et al. Iloprost improves endothelial barrier function in LPS-induced lung injury. Eur Respir J 2012; PMID: 22790920.
12. John J, Palevsky H. Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. Expert Rev Clin Pharmacol 2011; 2 (4): 197–205.
13. Kirbas A, Yalcin Y, Tanrikulu N et al. Comparison of inhaled nitric oxide and aerosolized iloprost in pulmonary hypertension in children with congenital heart surgery. J Cardiol 2012; 4 (19): 387–94.
14. Gokce I, Kahveci H, Turkyilmaz Z et al. Inhaled iloprost in the treatment of pulmonary hypertension in very low birth weight infants: a report of two cases. J Pak Med Assoc 2012; 4 (62): 388–91.
15. Yang SI, Chung WJ, Jung SH, Choi DY. Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome. Pediatr Cardiol 2012; 5 (33): 744–8.
16. Keith RL, Blatchford PJ, Kittelson J et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) 2011; 6 (4): 793–802.
17. Darcin OT, Zor MH, Sahin V et al. Effect of Iloprost on renal function in patients undergoing coronary artery bypass grafting: a clinical study. Ann Thorac Cardiovasc Surg 2012; PMID: 22785552.
18. Ege T, Gur O, Karadag CH, Duran E. Evaluation of iloprost to prevent vasospasm in coronary artery bypass grafts. J Int Med Res 2010; 5 (38): 1759–63.
19. Canacankatan N, Sucu N, Aytacoglu B et al. Affirmative effects of iloprost on apoptosis during ischemia-reperfusion injury in kidney as a distant organ. Ren Fail 2012; 1 (34): 111–8.
20. Brodszky V, Farkas K, Járai Z et al. Effectiveness of prostanoids in patients with critical leg ischemia. Orv Hetil 2011; 152 (51): 2047–55.
21. Blardi P, de Lalla A, Pieragalli D et al. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease. Prostaglandins Other Lipid Mediat 2006; 80 (3–4): 175–82.
22. Piaggesi A, Vallini V, Iacopi E et al. Iloprost in the management of peripheral arterial disease in patients with diabetes mellitus. Minerva Cardioangiol 2011; 1 (59): 101–18.
23. Yeh CH, Kuo CH, Yang SN et al. Prostaglandin I2 analogs suppress tumor necrosis factor a production and the maturation of human monocyte-derived dendritic cells. J Investig Med 2011; 7 (59): 1109–15.
24. Karatepe O, Cakir A, Unal O et al. Iloprost reduces colonic injury in ischemic colitis in rats. Acta Cir Bras 2011; 3 (26): 220–6.
25. Muzaffar S, Shukla N, Massey Y et al. NADPH oxidase 1 mediates upregulation of thromboxane A2 synthase in human vascular smooth muscle cells: inhibition with iloprost. Eur J Pharmacol 2011; 658 (2–3): 187–92.
2. Fetalvero KM, Martin KA, Hwa J. Cardioprotective prostacyclin signaling in vascular smooth musle. Prostaglandins Other Lipid Mediators 2007; 82: 109–18.
3. Мари Р., Гренер Д., Мейес П. Метаболизм ненасыщенных жирных кислот и эйказаноидов. М.: Мир, 1993.
4. Ольбинская Л.И., Литвицкий П.Ф. Коронарная и миокардиальная недостаточность. М.: Медицина, 1986.
5. Moncada S, Vane J. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmac Rev 1979; 30: 292–305.
6. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Современные подходы к лечению пациентов с легочной гипертензией в свете рекомендаций Европейского Общества кардиологов. Cons. med. 2005;7 (11): 957–62.
7. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–9.
8. Olschewski H, Hoeper MM, Behr J et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 2010; 104: 731–40.
9. Guo XX, Tian Z, Liu YT et al. Effects of inhaled aerosolized iloprost in adult patients with pulmonary arterial hypertension on right heart functions. Zhonghua Yi Xue Za Zhi 2011; 40 (91): 2832–6.
10. Gabrielli LA, Castro PF, Godoy I et al. Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients. J Card Fail 2011; 12 (17): 1012–7.
11. Birukova AA, Wu T, Tian Y et al. Iloprost improves endothelial barrier function in LPS-induced lung injury. Eur Respir J 2012; PMID: 22790920.
12. John J, Palevsky H. Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. Expert Rev Clin Pharmacol 2011; 2 (4): 197–205.
13. Kirbas A, Yalcin Y, Tanrikulu N et al. Comparison of inhaled nitric oxide and aerosolized iloprost in pulmonary hypertension in children with congenital heart surgery. J Cardiol 2012; 4 (19): 387–94.
14. Gokce I, Kahveci H, Turkyilmaz Z et al. Inhaled iloprost in the treatment of pulmonary hypertension in very low birth weight infants: a report of two cases. J Pak Med Assoc 2012; 4 (62): 388–91.
15. Yang SI, Chung WJ, Jung SH, Choi DY. Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome. Pediatr Cardiol 2012; 5 (33): 744–8.
16. Keith RL, Blatchford PJ, Kittelson J et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) 2011; 6 (4): 793–802.
17. Darcin OT, Zor MH, Sahin V et al. Effect of Iloprost on renal function in patients undergoing coronary artery bypass grafting: a clinical study. Ann Thorac Cardiovasc Surg 2012; PMID: 22785552.
18. Ege T, Gur O, Karadag CH, Duran E. Evaluation of iloprost to prevent vasospasm in coronary artery bypass grafts. J Int Med Res 2010; 5 (38): 1759–63.
19. Canacankatan N, Sucu N, Aytacoglu B et al. Affirmative effects of iloprost on apoptosis during ischemia-reperfusion injury in kidney as a distant organ. Ren Fail 2012; 1 (34): 111–8.
20. Brodszky V, Farkas K, Járai Z et al. Effectiveness of prostanoids in patients with critical leg ischemia. Orv Hetil 2011; 152 (51): 2047–55.
21. Blardi P, de Lalla A, Pieragalli D et al. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease. Prostaglandins Other Lipid Mediat 2006; 80 (3–4): 175–82.
22. Piaggesi A, Vallini V, Iacopi E et al. Iloprost in the management of peripheral arterial disease in patients with diabetes mellitus. Minerva Cardioangiol 2011; 1 (59): 101–18.
23. Yeh CH, Kuo CH, Yang SN et al. Prostaglandin I2 analogs suppress tumor necrosis factor a production and the maturation of human monocyte-derived dendritic cells. J Investig Med 2011; 7 (59): 1109–15.
24. Karatepe O, Cakir A, Unal O et al. Iloprost reduces colonic injury in ischemic colitis in rats. Acta Cir Bras 2011; 3 (26): 220–6.
25. Muzaffar S, Shukla N, Massey Y et al. NADPH oxidase 1 mediates upregulation of thromboxane A2 synthase in human vascular smooth muscle cells: inhibition with iloprost. Eur J Pharmacol 2011; 658 (2–3): 187–92.
Авторы
А.И.Инжутова
ГБОУ ВПО Красноярский государственный медицинский университет им. проф. В.Ф.Войно-Ясенецкого
ГБОУ ВПО Красноярский государственный медицинский университет им. проф. В.Ф.Войно-Ясенецкого
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.